There's a good reason that I always include the warning that small-cap med-techs carry above average risks, and LipoScience (LPDX)
dutifully provided an example last week. Due in part to system
placement delays and delays in ramping up new sales reps, this emerging
diagnostics company missed expectations for the first quarter and
lowered guidance for the rest of the year.
Retribution was swift
and severe - the shares tanked 25% in a single day. Now the question for
investors is whether there is still an opportunity here and where it's
worth the risks to buy shares in the hopes of realizing that
opportunity.
Read the full article here:
LipoScience Gives Its Shareholders Chest Pains
No comments:
Post a Comment